Lunai Bioworks has entered an exclusive worldwide license and collaboration with Tanaist to integrate human cellular phenotyping into its AI-driven Parkinson's disease platform. This partnership aims to validate patient subtypes identified by Lunai's AI tools by linking them to biological mechanisms and biomarkers through Tanaist's cellular phenotyping technology. The collaboration will test the reproducibility and biological relevance of these subtypes across multiple patient cohorts, advancing biomarker and therapeutic target development. This step strengthens Lunai's approach to translating AI discoveries into actionable treatments for Parkinson's disease.
Lunai Bioworks' recent expansion in Parkinson's disease research is presented here with relevant market data for context. For readers following the health sector, 50 of 101 priced US health stocks rose and 41 fell on Pluang. Notable movers include ADPT at USD 27.26 with a 2.15% decline, MRNA at USD 169.49 down 1.99%, and ABEO at USD 5.57 down 1.76%, as of Sep 22, 2026 19:02 WIB.
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
A director at FormFactor sold 2,100 shares, indicating a notable insider transaction. Such sales can reflect personal financial decisions or strategic portfolio adjustments by company insiders. Investors often watch these moves for potential signals ...
